Rare Disease research is innovative. The Orphan Drug industry has always embraced the NEW. This is why at the World Orphan Drug Congress USA, we get to delve into the worlds of Digital Health, Real World Evidence, Gene Therapy, Biosimilars and more…
At last year’s edition, Gigi Hirsch, Executive Director, MIT Center for Biomedical Innovation joined us to discuss Adaptive Biomedical Innovation.
What is Adaptive Biomedical Innovation?
ABI is a strategic framework of innovation that aims to deliver new, better, affordable treatments to the right patients faster.
Why the need to change how we innovate?
There are many challenges facing innovation. Firstly, the patients can’t wait. And more challenging, science often advances before the system.
“Knowledge is an unending adventure at the edge of uncertainty.” – Jacob Bronowski(1908-1974)British mathematician, biologist, author & inventor
Join us at the World Orphan Drug Congress USA 2017, where scientific innovation meets commercialization.